Skip to main content
. 2017 Mar 1;42(8):1619–1629. doi: 10.1038/npp.2017.21

Figure 1.

Figure 1

The KMO inhibitor Ro 61-8048 dose-dependently reduces nicotine self-administration under a fixed-ratio (FR1) schedule in rats. (a–c) Nose-poke responses in active and inactive holes during single-session (2 h) nicotine self-administration (30 μg/kg/injection) tests with vehicle or Ro 61-8048 (30, 56, and 100 mg/kg, i.p.) pretreatment 40 min before the session (n=14). (a) The first day of treatment with Ro 61-8048 is shown. Responses in active (b) and inactive (c) holes per session (n=12) are shown during 3 consecutive days of pretreatment with 30 or 100 mg/kg of Ro 61-8048 (sessions 1–3) compared with vehicle treatment (baseline). Pretreatment with PNU120596 (1 mg/kg, i.p., 60 min before the session) did not prevent the effect of Ro 61-8048 (100 mg/kg) on nicotine self-administration. (d–f) Responses in active and inactive holes during a 2 h session are shown during 3-day pretreatment with vehicle (n=8), PNU120596 (n=4), Ro 61-8048 (n=3), or a combination of Ro 61-8048 and PNU120596 (n=4) (d). Responses in active (e) and inactive (f) holes are also shown during 3 consecutive days of pretreatment with Ro 61-8048 (n=10), PNU120596 (n=4), or a combination of Ro 61-8084 and PNU120596 (sessions 1–3; n=12) compared with vehicle treatment (baseline). All data are mean±SEM. *Significantly different from vehicle (0 mg/kg Ro 61-8048 or baseline), Tukey’s test, *p<0.05, **p<0.01, ***p<0.001. Ro, Ro 61-8048; PNU, PNU120596.